Knocking down NUPR1 in liver cancer, pancreatic cancer, glioma, and lung cancer inhibited cell proliferation, migration, and invasion and EMT transformation; it also promoted apoptosis, increased tumor drug sensitivity, and participated in MAPK and TGF-β pathways—MAPK and TGF-β were potential oncoproteins (34–36). This evidence concerns the gene TGFB1 and glioma.